NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by The Bellwether Report.

Combination to Accelerate Growth and Broaden Presence in Women's Health Market

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=3827066 for the full story.

Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=3819513 for the full story.

These are some of the top upgrades or positive analyst calls we have seen this Tuesday morning in early pre-market trading hours: eHealth ( NASDAQ: EHTH) Raised to Perform from Underperform at Oppenheimer. F5 Networks ( NASDAQ: FFIV) Started as Buy at Pacific Growth. Foundry Networks ( NASDAQ: FDRY) Started as Buy at Pacific Growth. Lennar ( NYSE: LEN) Raised to Neutral from Sell at UBS. OptionsXpress ( NASDAQ: OXPS) Started as Market Outperform at JMP Securities. Schering-Plough ( NYSE: SGP) Raised to Overweight from Equal-weight at Lehman Brothers. Third Wave ( NASDAQ: TWTI) Cut to Hold from Buy at Deutsche Bank. Jon C. Ogg July 15,...

The major market indices fell for the sixth consecutive week, yet the fear indices are showing only small gains.

Invitrogen gets a positive review from the FDA for one of its tests.

Enzon Pharmaceuticals? (ENZN) key product Abelcet, a treatment for fungal infections, sales continued to deteriorate in 2008. Further, another major source of revenue, Royalty, is also under pressure from competition. However, sales in two other products, Oncaspar (for acute lymphoblastic leukemia) and Adagen (for severe combined immunodeficiency disease) are picking up momentum and offsetting the sales decline from Abelcet and Royalty. We are impressed with strong sales growth of Oncaspar. We expect total revenue to remain stable or experience modest growth in the coming years while the company is progressing well with its clinical developments. Enzon is also advancing its pipeline to drive long-term growth. We maintain our Hold rating on the shares. We see a balanced risk/reward profile for Enzon. In our view, there are limited near-term catalysts to[More...]

DST Systems, Inc. (DST) was hit hard in the first quarter by the loss of share owner accounts that were converted to less profitable sub-accounts. We believe this is likely to be a headwind for the foreseeable future as mutual fund companies continue to offload this function to broker dealers. We maintain our Hold rating on DST shares and set our target price to $67.00. DST's leadership position and... [More...]

UP
Third Wave Technologies Inc (TWTI)
Pacific Ethanol Inc (PEIX)
Zvue Corp (ZVUE)
CIT Group Inc (CIT)
McDonald's Corporation (MCD)
DOWN
Royal Bk Scotland Group Plc (RBS)
Royal Energy Inc (ROYL)
Net Servicos De Comunicacao (NETC)
Taser Intl Inc (TASR)
Merrill Lynch & Co., Inc (MER)

This week award-winning technical analyst & stock picker Harry Boxer reviews three new stocks on the long side that are breaking out and look very bullish.

Major indices closed up the week here the details:
Nasdaq -4,6%
Dow Jones -4,2%
S&P 500 -4,9%

Here The Weekly Movers:

GAINERS
Gigabeam Corporation (GGBM)
Telular Corporation (WRLS)
Third Wave Technologies, Inc. (TWTI)
Dade Behring Holdings, Inc. (DADE)
Republic Property Trust (RPB)
Hanesbrands Inc. (HBI)
LOSERS
Isilon Systems, Inc. (ISLN)
Fremont General Corporation (FMT)
WCI Communities, Inc. (WCI)
Skechers USA, Inc. (SKX)
RPC, Inc. (RES)